Group 1 - The core business of the company is providing Clinical Information Management Systems (CIS) and overall solutions for clinical informationization, with a focus on advanced technologies like mobile internet, IoT, and big data [2] - The company's flagship product, the DoCare series, serves critical areas such as operating rooms, intensive care units, pre-hospital emergency care, and in-hospital emergency services, covering over 2,400 medical institutions nationwide, including nearly 1,200 tertiary hospitals [2] - The company has achieved significant recognition, including being named a national high-tech enterprise and receiving multiple awards for its innovative products and contributions to digital healthcare [2] Group 2 - For Q1 2025, the company reported a revenue of 63.34 million yuan, a year-on-year decrease of 43.13%, while net profit increased by 138.55% to 23.60 million yuan, with a gross margin of 66.10% [3] - The company's stock closed at 14.88 yuan, up 1.78%, with a latest price-to-book ratio of 5.54 and a total market capitalization of 4.557 billion yuan [1] - The company is actively exploring the application of cutting-edge technologies such as 5G, IoT, and AI in low-altitude economic sectors, including emergency rescue services using helicopters and drones [2]

证券代码：301337 证券简称：亚华电子 投资者关系活动记录表 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 参与单位名称及人员姓名 线上参与公司2024年度网上业绩说明会的投资者 时间 2025年05月08日 15:00-16:00 地点 价值在线（https://www.ir-online.cn/）网络互动 上市公司接待人员姓名 实控人、董事长 耿斌 董事、总经理 向晖 独立董事 吴忠堂 财务总监、董事会秘书 于雷 投资者关系活动主要内容 介绍 1.公司提到将把握医疗领域旧病房更新改造的政策机遇，具体 有哪些项目已经启动或正在规划中？ 答:根据国务院《推动大规模设备更新和消费品以旧换新行动 方案》要求：加强优质高效医疗卫生服务体系建设，推进医疗卫生 机构装备和信息化设施迭代升级……推动医疗机构病房改造提升， 补齐病房环境与设施短板。公司"IP两线组网"技术，凭借"可靠 +便捷施工"双擎，切实为旧病房改造项目提供更优落地方案。截 至目前，上海第一人民医院、大同市第五人民医院、海南医科大学 第二附属医院等项目 ...

Core Viewpoint - The company is experiencing short-term pressure on its performance, with a focus on cost reduction and efficiency improvement to enhance operational quality [2] Financial Performance - In Q1 2025, the company reported revenue of 345 million yuan, a year-on-year decrease of 30.24%, and a net profit attributable to shareholders of 5.29 million yuan, down 68.18% [1] - For the full year 2024, the company achieved revenue of 2.782 billion yuan, a decline of 12.05%, and a net profit of 88 million yuan, down 75.45% [1] Profitability Metrics - In Q1 2025, the gross margin and net margin were 34.46% and -0.97%, respectively, showing an increase of 0.75 percentage points and a decrease of 2.28 percentage points year-on-year [2] - For 2024, the gross margin and net margin were 41.68% and 1.80%, reflecting a decline of 3.32 percentage points and 8.24 percentage points year-on-year [2] Business Segments - The healthcare information technology segment generated revenue of 2.445 billion yuan in 2024, a decrease of 14.17%, accounting for 87.88% of total revenue [3] - The "Internet + Healthcare" segment showed growth, with revenue of 337 million yuan in 2024, up 7.83%, representing 12.11% of total revenue [3] Product Development - The WiNEX product has entered the mass delivery phase, supporting internet operations and international adaptation, with 75 core business systems achieving multilingual support [4] - The company is enhancing its AI capabilities with the release of WiNGPT2.8 and WiNEX Copilot2.1, deploying AI applications to over 20 users by the end of 2024 [5] Future Outlook - The company anticipates continued optimization of its organizational structure and personnel, with expectations for improved profitability driven by the demand for the new WiNEX product [2] - Revenue projections for 2025-2027 are estimated at 3.036 billion yuan, 3.343 billion yuan, and 3.715 billion yuan, with net profits of 305 million yuan, 374 million yuan, and 452 million yuan, respectively [5]

Core Viewpoint - The sale of 100% equity in Yihui Technology by Sichuang Medical to Shanhai Digital for approximately 299.6 million RMB marks a strategic shift for Sichuang Medical, allowing it to divest from its underperforming smart healthcare business and focus on the commercial intelligence sector [1][2]. Group 1: Company Strategy - The primary objective of the transaction is to concentrate resources and funding on the commercial intelligence business, which is expected to optimize the company's business structure and promote high-quality development [1][2]. - After the sale, Yihui Technology will no longer be included in the consolidated financial statements, which is anticipated to improve the company's financial condition and performance metrics [1][3]. - The commercial intelligence business is based on EAS and RFID research and production, providing deep IoT solutions across various industries, with a strong market position in both EAS and RFID sectors [2]. Group 2: Financial Impact - In the period from January to October 2024, Yihui Technology reported revenues of 111 million RMB and a net loss of 316 million RMB, significantly dragging down the overall performance of Sichuang Medical [1]. - The divestiture is expected to enhance asset quality and profitability, as well as increase working capital reserves, thereby supporting the company's focus on commercial intelligence [1][2]. Group 3: Market Position and Future Outlook - The strategic support from state-owned enterprises is crucial for the development of the smart healthcare sector, highlighting the importance of national strategic technology forces [2]. - The transaction is viewed as a positive move that will not compromise the integrity of the company's operations but rather enhance profitability and long-term shareholder value [3].

一、市场指数 与成交额 ：缩量反弹，沪指收于 3300 点之下 今日， A 股三大指数延续震荡格局。截至收盘，上证指数 3295.06 点，下跌 0.07% ；深证 成指上涨 0.39% ，创业板指表现最强，涨幅 0.59% 。两市成交额合计 1.1 万亿元，市场交 投情绪趋于平淡。 从资金面看，央行今日开展 6000 亿元中期借贷便利（ MLF ）操作，净投放 5000 亿元流动 性，为市场注入信心。叠加中央汇金一季度增持沪深 300ETF 的稳定作用，市场下行风险被 有效对冲。 二、领涨板块：电力、 AI 医疗与算力概念活跃 电力板块：煤价下行叠加容量电价机制优化，火电企业盈利预期改善。华银电力、西昌电力等 涨停，机构预计 4 月全社会用电量增速或达 4.5%-5.5% 。 AI 医疗与算力概念：受工信部等七部门《医药工业数智化转型实施方案》推动， AI 医疗板块 活跃，塞力医疗、创业慧康等涨幅居前。算力产业链同步反弹，拓维信息、鸿博股份涨停，国 产算力需求激增成为长期增长逻辑。 四、 总结 当前市场仍处于震荡筑底阶段， 同时 政策托底与流动性宽松为结构性行情提供支撑 。期待 5 月出现新的行情。 欢迎大 ...

Financial Performance - The company reported a basic earnings per share of -0.0600 yuan for Q1 2025, an improvement of 25% compared to -0.0800 yuan in Q1 2024, but a decline from 0.0500 yuan in Q1 2023 [1] - The net profit for Q1 2025 was -0.06 billion yuan, showing a 25% improvement from -0.08 billion yuan in Q1 2024, but a decrease from 0.04 billion yuan in Q1 2023 [1] - The operating revenue increased by 33.33% to 0.4 billion yuan in Q1 2025 from 0.3 billion yuan in Q1 2024, but decreased from 0.59 billion yuan in Q1 2023 [1] - The return on equity was -0.54% in Q1 2025, an improvement from -0.72% in Q1 2024, but a decline from 1.17% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 2.7582 million shares, accounting for 7.1% of the circulating shares, with a decrease of 1.2615 million shares compared to the previous period [1] - Notable changes in the top shareholders include the entry of Zhao Yongzhang, Chen Liping, and Chu Yazhou, while Sun Chengli, Zhou Lei, and Zhao Chen exited the top ten shareholders [2] Dividend Policy - The company has decided not to distribute dividends or transfer shares in this period [3]

Group 1 - A-share DRG/DIP concept stocks have shown strong performance, with Chuangye Huikang rising over 6% [1] - Saily Medical has increased by more than 5% [1] - Huaping Co., Jiahe Meikang, and Dian Diagnostics have all risen over 3% [1]

单位：元 登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 上述财务指标或其加总数是否与公司已披露季度报告、半年度报告相关财务指标存在重大差异 □是 √否 4、股本及股东情况 （1） 普通股股东和表决权恢复的优先股股东数量及前10名股东持股情况表 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 √不适用 公司报告期无优先股股东持股情况。 5、在年度报告批准报出日存续的债券情况 □适用 √不适用 三、重要事项 1、关于使用募集资金置换预先投入的自筹资金事项 公司于2024年1月12日召开第十一届董事会第二十三次会议、第十一届监事会第十四次会议，审议通过 了《关于使用募集资金置换预先投入的自筹资金的议案》，为保障公司募投项目实施进度，在募集资金 到位前，公司以自筹资金对募投项目进行了预先投入并支付了部分发行费用共计4,129.47万元，公司决 定使用募集资金置换上述先期投入。 具体内容详见公司于2024年1月13日在《中国证券报》《上海证券报》《证券时报》 ...

前十大流通股东累计持有： 29910.53万股，累计占流通股比： 31.32%，较上期变化： -367.81万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.0106 | -0.0876 | 87.9 | -0.0930 | | 每股净资产（元） | 1.43 | 1.44 | -0.69 | 0.78 | | 每股公积金(元) | 0.72 | 0.74 | -2.7 | 0.04 | | 每股未分配利润(元) | -0.18 | -0.17 | -5.88 | -0.09 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.57 | 3.3 | 8.18 | 3.11 | | 净利润(亿元) | -0.1 | -0.8 | 87.5 | -0.84 | | 净资产收益率(%) | -0.73 | -10.42 | 92.99 | -11.29 | 数据四舍五入，查看更多财务数 ...

1、 适度的乐观才是对的。而在这个前提下，你必须学会选择自己的战场。 2、 从投资回报的角度看，我在过去二十年中作为 Founders Fund创始合伙人尝试过的各类投资里， 表现最差的两个领域，就是教育软件和医疗信息化。 3、 当所有人都认同这是一件 "显而易见的大事"时，如果你不能拿出一种完全不同的视角，你就几乎 没戏。 两人多年好友，对话没有太多寒暄，直接切入问题本身： "在一个越来越多系统坏掉的时代，聪明人该怎么选择战场？" 他吐槽了很多美国政府系统失灵的、不可思议之处。比如 地铁 ， 美国修建 1 英里 需要 10 亿美元， 10倍于伦敦搭建的成本；政 府预算明面上写着 "援助非洲"，实际上却是给政党选举买单 …… 反倒是那些不那么热门、但你有独特认知差的地方，更容易挖出真正的机会。 4、 你不能什么都干。你不能像一个冲浪者，在一个没有浪的平静日子里拼命划水。 你要等到有浪来的时候，在恰当的位置发力 ，才会有效果。 彼得 ·蒂尔（Peter Thiel） 在中国 最广为人知的身份，可能是《从 0到1》 的 作者，是支持特朗普的 硅谷少数派，是与马斯克曾在 PayPal一起打天下的早期合伙人。 他是 ...